Table 4.
Reported complex III inhibitors.
| Compound | Microorganism targeted | IC50 | MIC50 | Toxicity | Inhibition mechanism |
|---|---|---|---|---|---|
|
| |||||
| Azoxystrobin | Pythium spp. | 27 nM (Dreinert et al. 2018) | 0.25–6 μM (Matić et al. 2019) | Acute oral, dermal, inhalation (Rodrigues et al. 2013) | Qo site |
| Ametoctradin | Pythium spp. | 90 nM | Acute oral, dermal, inhalation (European Food Safety Authority 2012) | Qo/Qi site | |
| Cyazofamid | P. insidiosum | >10 mM (Dreinert et al. 2018) | ≤3 μM (Yolanda et al. 2024) | Nephrotoxic (Federal Register 2020) | Qi site |
| Atovaquone | P. falciparum | 3 nM (Biagini et al. 2008) | 1 nM (Biagini et al. 2008) | Hepatotoxic (rare) (National Institute of Diabetes and Digestive and Kidney Diseases 2012d) | Qo site |
| Telacebec | M. tuberculosis | 1 nM (Pethe et al. 2013) | 3 nM (Pethe et al. 2013) | None observed (Kim et al. 2022) | Qo site |
| Lansoprazole | M. tuberculosis | 0.5 μM ((Kovalova et al. 2024) | 2 μM (Rybniker et al. 2015) | Hepatotoxic (rare) (National Institute of Diabetes and Digestive and Kidney Diseases, 2012e) | Qo site |
| Siccanin | P. falciparum | 8 μM (Komatsuya et al. 2022) | 8 μM (Komatsuya et al. 2022) | DLD-1, 34 μM HDF 16 μM (Komatsuya et al. 2022) |
Qi site |